

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner:

Unassigned

Stephen D. Pacetti

Serial No.

10/805,036

Art Unit:

1614

Filed:

March 16, 2004

Title:

Biologically Absorbable Coatings for Implantable Devices Based on

Copolymers Having Ester Bonds and Methods for Fabricating the Same

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §\$1.97-1.98, Applicant hereby notifies the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicant has not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and other non-patent documents have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant reserves the right to dispute the listed documents as prior art during examination. Furthermore, Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

l

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: July 14, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P. One Maritime Plaza, Suite 300 San Francisco, CA 94111 Telephone (415) 954-0200 Facsimile (415) 393-9887 Respectfully submitted,

Brian S. Boyer, Ph.D. Attorney for Applicant

Reg. No. 52,643



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner:

Unassigned

Stephen D. Pacetti

Serial No.

10/805,036

Art Unit:

1614

Filed:

March 16, 2004

Title:

Biologically Absorbable Coatings for Implantable Devices Based on

Copolymers Having Ester Bonds and Methods for Fabricating the Same

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §\$1.97-1.98, Applicant hereby notifies the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicant has not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and other non-patent documents have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant reserves the right to dispute the listed documents as prior art during examination. Furthermore, Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: July 14, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P. One Maritime Plaza, Suite 300 San Francisco, CA 94111 Telephone (415) 954-0200 Facsimile (415) 393-9887 Respectfully submitted,

Brian S. Boyer, Ph.D. Attorney for Applicant

Reg. No. 52,643

Please upe a plus sig	ın (+) inside this box	→ [+]		Approve	i for use throug	PTO/SB/21 (08-00) ph 10/31/2002. OMB 0651-0031
			U. equired to re		000 110 0	PARTMENT OF COMMERCE isplays a valid OMB control number.
OFFIS				ation Number	10/805,036	
	ISMITTAL		Filing	Date	March 16,	2004
F	ORM		First N	amed Inventor	Stephen D	. Pacetti
(to be used for all cor	respondence after in	itial filing)	Group	Art Unit	1614	
			Exami	ner Name	Unknown	
Total Number of Pag	ges in This Submission (s)	1 14	Attorn	ey Docket Number	50623.311	
		ENCL	OSURES	(check all that apply)		
Deposit Account (Authorization	07-1850		ment Pap Application)		After All Group	owance Communication to
Postage Paid Ret	urn Postcard			rmal Sheets with rawings Transmittal		Communication to Board of and Interferences
Amendment / Res	sponse	Licens	ing-related	d Papers		Communication to Group Notice, Brief, Reply Brief)
Amendment Trans duplicate)	smittal Letter (in	Petition	n		Propriet	ary Information
Affidavits/dec	laration(s)	Petition Provisi	Petition to Convert to a Provisional Application			etter `
Petition for Extens			Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):	
Information Disclo			Terminal Disclaimer			npublished Patent lications;
- citing 257 Referen		Request for Refund		1	Foreign Patent Documents; Other Documents	
Express Mail Labo		☐ CD, Ni	umber of (CD(s)		
Certified Copy of Document(s)	Priority	Rema	ırks			
Response to Miss Incomplete Applic						
Response to Parts under 3 1.52 or 1.53						
	SIGNA	TURE OF	APPLICA	ANT, ATTORNEY, O	R AGENT	
Firm Squire, Sanders & Dempsey L. Brian S. Boyer, Ph.D., Reg. No				•		
Signature Kuan S-Hax						
Date	Date July 17, 2004					
		CE	RTIFICA	TE OF MAILING		
	·	- ·				irst class mail in an envelope
addressed to: Comm	nissioner for Patents,	P.O. Box 14	150, Alexa	ndria, VA 22313-1450	on this date:	July <u>//,</u> 2004
Typed or printed nam	ne Dilora Hadda	<u></u>				
Signature	XXXII				Date	July <u>/ 4</u> , 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

10/805,036

FORM PTO-1443 (Modified)

US DEPARTMENT OF COMMERCE

US Patent and Trademark Office

Application No. Docket No. 50623.311 Applicant

Approved for use to a puch 1001/2002 US Patent and Trademain INFORMATION DISCLOSURE CITATION in an Application

(Use several sheets if necessary)

Stephen D. Pacetti

Group Art Unit Filing Date March 16, 2004 1614

			U.S. PATE	ENT DOCUMENTS			
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	2,386,454	10/9/45	Frosch et al.	260	78	11/22/40
-	A2	3,773,737	11/20/73	Goodman et al.	260	78	6/9/71
	A3	3,849,514	11/19/74	Gray, Jr. et al.	260	857	9/5/69
-	A4	4,226,243	10/7/80	Shalaby et al.	128	335.5	7/27/79
	A5	4,329,383	5/11/82	Joh	428	36	7/21/80
	A6	4,343,931	8/10/82	Barrows	528	291	12/17/79
	A7	4,529,792	7/16/85	Barrows	528	291	5/6/82
	A8	4,611,051	9/9/86	Hayes et al.	528	295.3	12/31/85
•	A9	4,656,242	4/7/87	Swan et al.	528	295.3	6/7/85
-	A10	4,882,168	11/21/89	Casey et al.	424	468	9/5/86
	A11	4,941,870	7/17/90	Okada et al.	600	36	12/30/88
	A12	4,977,901	12/18/90	Ofstead	128	772	4/6/90
	A13	5,100,992	3/31/92	Cohn et al.	424	501	5/3/90
	A14	5,112,457	5/12/92	Marchant	204	165	7/23/90
	A15	5,133,742	7/28/92	Pinchuk	623	1	11/14/91
	A16	5,165,919	11/24/92	Sasaki et al.	424	488	9/26/90
	A17	5,219,980	6/15/93	Swidler	528	272	.4/16/92
	A18	5,272,012	12/21/93	Opolski	428	423.1	1/29/92
	A19	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91
	A20	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92
	A21	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91
	A22	5,306,501	. 4/26/94	Viegas et al.	424	423	11/8/91
	A23	5,306,786	4/26/94	Moens et al.	525	437	12/16/91
	A24	5,328,471	7/12/94	Slepian	604	101	8/4/93
	A25	5,330,768	7/19/94	Park et al.	424	501	7/5/91
	A26	5,380,299	1/10/95	Fearnot et al.	604	265	8/30/93

	A27	5,417,981	5/23/95	Endo et al.	424	486	4/28/93
-	A28	5,447,724	9/5/95	Helmus et al.	424	426	11/15/93
	A29	5,455,040	10/3/95	Marchant	424	426	11/19/92
	A30	5,462,990	10/31/95	Hubbell et al.	525	54.1	10/5/93
	A31	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93
	A32	5,485,496	1/16/96	Lee et al.	378	64	
	A33	5,516,881	5/14/96	Lee et al.	528	320	8/10/94
	A34	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95
•	A35	5,578,073	· 11/26/96	Haimovich et al.	623	1	9/16/94
	A36	5,605,696	2/25/97	Eury et al.	424	423	3/30/95
	A37	5,609,629	3/11/97	Fearnot et al.	623	1	6/7/95
	A38	5,610,241	3/11/97	Lee et al.	525	411	5/7/96
	A39	5,624,411	4/29/97	Tuch	604	265	6/7/95
	A40	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	. A41	5,644,020	7/1/97	Timmermann et al.	528	288	5/10/96
	A42	5,649,977	7/22/97	Campbell	623	1	9/22/94
	- A43	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
	A44	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A45	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
	A46	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
	A47	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A48	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A49	5,711,958	1/27/98	Cohn et al.	424	423	7/11/96
	A50	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A51	5,721,131	2/24/98	Rudolph et al.	435	240	4/28/94
	A52	5,735,897	4/7/98	Buirge	623	12	1/2/97
	A53	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A54	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A55	5,783,657	7/21/98	Pavlin et al.	528	310	10/18/96
	A56	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A57	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A58	5,820,917	10/13/98	Tuch	427	2.1	6/7/95

A59	5,824,048	10/20/98	Tuch	623	1	10/9/96
A60	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
A61	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
A62	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
A63	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
A64	5,849,859	12/15/98	Acemoglu	528	271	3/23/93
A65	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
A66	5,854,376	12/29/98	Higashi	528	288	3/11/96
A67	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
. A68	5,865,814	2/2/99	Tuch	604	265	8/6/97
A69	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
A70	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
A71	5,876,433	3/2/99	Lunn	623	1	5/29/96
A72	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
A73	5,902,875	5/11/99	Roby et al.	528	310	1/28/98
. A74	5,905,168	5/18/99	Dos Santos et al.	562	590	12/10/93
A75	5,910,564	6/8/99	Gruning et al.	528	310	12/6/96
A76	5,914,387	6/22/99	Roby et al.	528	310	1/28/98
A77	5,919,893	7/6/99	Roby et al.	525	411	1/28/98
A78	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
A79	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
A80	5,958,385	9/28/99	Tondeur et al.	424	61	9/28/95
A81	5,980,928	11/9/99	Terry	424	427	7/29/97
A82	5,980,972	11/9/99	Ding	427	2.24	9/22/97
A83	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
A84	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
A85	6,011,125	1/4/00	Lohmeijer et al.	525	440	9/25/98
A86	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
A87	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
A88	6,034,204	3/7/00	Mohr et al.	528	328	8/7/98
A89	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
A90	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
A91	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97

					•		
	A92	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A93	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A94	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A95	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A96	6,096,070	8/1/00	Ragheb et al.	623	1	. 5/16/96
	A97	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A98	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A99	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A100	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A101	6,120,491	9/19/00	Kohn et al.	604	502	4/7/98
	A102	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A103	6,120,788	9/19/00	Barrows	424	426	10/16/98
	. A104	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A105	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A106	6,136,333	10/24/00	Cohn et al.	424	423	7/11/97
	A107	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	_. A108	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A109	6,172,167	1/9/01	Stapert et al.	525	420	6/27/97
	A110	6,203,551	3/20/01	Wu	606	108	10/4/99
	A111	6,211,249	4/3/01	Cohn et al.	514	772.1	1/13/98
	A112	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A113	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A114	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A115	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
	A116	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A117	6,258,121	7/10/01	` Yang et al.	623	1.46	7/2/99
	A118	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A119	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A120	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A121	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
<u></u>	A122	6,331,313	12/18/01	Wong et al.	424	427	10/22/99

A123	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
A124	6,346,110	2/12/02	Wu	606	108	1/3/01
A125	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
A126	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
A127	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
A128	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
A129	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
A130	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
A131	6,503,538	1/7/03	Chu et al.	424	497	8/30/00
A132	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
A133	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
A134	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
A135	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
A136	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
A137	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
A138	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
. A139	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
A140	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
A141	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
A142	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
A143	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
A144	6,572,644	6/3/03	Moein	623	1.11	6/27/01
A145	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
A146	6,585,926	7/1/03	Mirzaee	264	400	8/31/00
A147	6,605,154	8/12/03	Villareal	118	500	5/31/01
A148	10/630,250		Pacetti et al.			7/30/03
A149	10/738,704		Pacetti et al.			12/16/03
A150	10/741,214		Pacetti			12/19/03
A151	10/750,139		DesNoyer et al.			12/30/03

	A152	10/816,072		Dugan et al.			3/3	1/04
	A153	10/835,656		Hossainy et al.			4/30	0/04
	A154	10/855,294		Pacetti et al.			5/26	5/04
	 	U.S. PATE	NT APPLICAT	ION PUBLICATION DOCL	JMENTS	<u>'</u>		
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class ·	Subclass	_	Date if opriate
	A155	2001/0018469	8/30/01	Chen et al.	523	121	12/2	8/00
	A156	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/2	1/01
•	A157	2002/0071822	6/13/02	Uhrich	424	78.37	7/27	7/01
	A158	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/1	9/00
•	A159	2002/0091433	7/11/02	Ding et al.	623	1.2	12/1	7/01
	A160	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	4/01
	A161	2003/0032767	2/13/03	Tada et al.	528	310	2/5	/01
	A162	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	0/02
	A163	2003/0099712	5/29/03	Jayaraman	424	486	11/2	6/01
			FOREIGN PA	ATENT DOCUMENTS				
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country .	Class	Subclass	Trans Yes	lation No
-	B1	SU 872531	10/15/81	Soviet Union			Х	
	B2	SU 876663	10/30/81	Soviet Union			Х	
	В3	SU 905228	2/15/82	Soviet Union			Х	
	B4	SU 790725	2/9/83	Soviet Union			Х	
	B5	SU 1016314	5/7/83	Soviet Union			Х	
	B6	SU 811750	9/23/83	Soviet Union			Х	
· · · · · · · · · · · · · · · · · · ·	B7	SU 1293518	2/28/87	Soviet Union			Х	
	B8	EP 0 301 856	2/1/89	European				
	B9	EP 0 396 429	11/7/90	European				
	B10	WO 91/12846	9/5/91	PCT				
	B11	EP 0 514 406	11/25/92	European				
	B12	DE 42 24 401	1/27/94	Germany			Х	
	B13	WO 94/09760	5/11/94	PCT				
	B14	EP 0 604 022	6/29/94	European				
	B15	EP 0 623 354	11/9/94	European				
	B16	WO 95/10989	4/27/95	PCT				

B48	2001-190687	7/17/01	Japan (Abstract)		x	
· B47	WO 01/49338	7/12/01	PCT			
B46	WO 01/45763	6/28/01	PCT			
B45	WO 01/17577	3/15/01	PCT			
B44	WO 01/15751	3/8/01	PCT	NI TO THE		
B43	WO 01/01890	1/11/01	PCT			
B42	WO 00/64506	11/2/00	PCT			
B41	WO 00/18446	4/6/00	PCT			
B40	WO 00/12147	3/9/00	PCT			_
B39	EP 0 982 041	3/1/00	European			
B38	WO 00/02599	1/20/00	PCT			
B37	EP 0 970 711	1/12/00	European			
B36	WO 99/63981	12/16/99	PCT			
B35	EP 0 953 320	11/3/99	European			
B34	WO 99/38546	8/5/99	PCT			
· B33	EP 0 923 953	6/23/99	European			
B32	EP 0 910 584	4/28/99	European			
. B31	WO 99/01118	1/14/99	PCT			
B30	EP 0 879 595	11/25/98	European			
B29	WO 98/36784	8/27/98	PCT			
B28	WO 98/32398	7/30/98	PCT			
B27	EP 0 850 651	7/1/98	European			
B26	WO 98/17331	4/30/98	PCT		,	
B25	EP 0 832 655	4/1/98	European			
· B24	WO 97/46590	12/11/97	PCT			
B23	WO 97/45105	12/4/97	PCT			
B22	EP 0 809 999	12/3/97	European			
B21	WO 97/10011	3/20/97	PCT			
B20	WO 96/40174	12/19/96	PCT			
B19	EP 0 716 836	6/19/96	European			
B18	EP 0 701 802	3/20/96	European			
B17	EP 0 665 023	8/2/95	European			

B49	WO 01/51027	7/19/01	PCT				
B50	WO 01/74414	10/11/01	PCT				
B51	WO 02/03890	1/17/02	PCT				
B52	WO 02/026162	4/4/02	PCT				
B53	WO 02/34311	5/2/02	PCT				
B54	WO 02/056790	7/25/02	PCT				
B55	WO 03/000308	1/3/03	PCT				
B56	EP 1 273 314	1/8/03	European				
B57	WO 03/022323	3/20/03	PCT				
B58	WO 03/028780	4/10/03	PCT				
B59	WO 03/037223	5/8/03	PCT				
B60	WO 03/039612	5/15/03	PCT				
	OTHER DO	CUMENTS (Incl	uding Author, Title, Date, Pertinent l	Pages, etc.)			
C1			he Dream Stent, Clinica 710:15 (<u>tt?req=1061848202959,</u> printed 8				
C2			complications by 30%, Clinica 73			 3).	
-	http://www.dialogweb	com/cgi/documer	t?req=1061847871753, printed 8	3/25/03 (2 p	ages).		
C3	Anonymous, Rolling (Abstract 434009), Re		Loading Device for Therapeutic 4-975 (June 2000).	Agent Deliv	ery or C	oated S	tent
C4			inate cardiology, Clinica 720:22 (tt?req=1061848017752, printed 8				
C5	Aoyagi et al., <i>Prepara</i> Journal of Controlled		d aliphatic polyester and applicat (1994).	tion to thern	no-respo	nsive m	aterial,
C6	Barath et al., Low Do. Injury, JACC 13(2): 2		rents Prevents Smooth Muscle C	ell Prolifera	tion Afte	r Endotl	helial
C7		ng of commercially	v available materials with a new h	neparinizabl	e materia	al, J. Bio	omed.
C8		re segment desig	n for drug delivery control of them 3 (2000).	mo-respons	sive polyi	meric m	icelles,
C9	Dev et al., Kinetics of	Drug Delivery to t	he Arterial Wall Via Polyurethane eterization and Cardiovascular D				
C10		of Intravascular	Stents with Genetically Engineere				
C11	Eigler et al., Local Art	igler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, istribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).					etics,
C12			ials, MRS Bulletin, pp. 33-38 (Se				
C13	Herdeg et al., <i>Antipro</i> 3:197-199 (1998).	liferative Stent Co	atings: Taxol and Related Compo	ounds, Sem	nin. Interv	vent. Ca	rdiol.
C14		adable Polymers l	Derived from Aminoacids, Macro	mol. Symp.	144, 7-3	2 (1999).
C15			oxy-Poly(Ester Amide)s, http://wy	vw.tech-			

	C16	Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).
	C17	Kataoka et al., Block copolymer micelles as vehicles for drug delivery, Journal of Controlled Release 24:119-132 (1993).
	C18	Katsarava et al., Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters and Aliphatic Dicarbolic Acids, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).
	C19	Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
	C20	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
•	C21	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
•	C22	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C23	Miyazaki et al., Antitumor Effect of Implanted Ethylenė-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C24	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C25	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C26	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).
•	C27	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C28	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C29	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).
	C30	Saotome, Y., et al., Novel Enzymatically Degradable Polymers Comprising .alphaAmino Acid, 1,2- Ethanediol, and Adipic Acid, Chemistry Letters, pp. 21-24, (1991).
	C31	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
	C32	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).
	C33	Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc. Med. 3(5):163-170 (1993).
	C34	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).
EXAMINER		DATE CONSIDERED
		erences considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.